Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

BMRN vs. ILMN: Which Stock Is the Better Value Option?

Illumina, Qnity Electronics and nVent Electric lead Zacks' latest Strong Buy picks as markets eye inflation, rates and global risks.

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Mid Cap Strategy”. A copy of the Q2 2026 investor letter can be downloaded here. In the quarter, equity markets posted strong returns as resilient economic growth and robust corporate earnings supported investor sentiment, although AI-related companies continued to dominate market […]

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Clinical momentum and NovaSeq X placements drive revenue guidance raise.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

In late July 2026, Illumina reported second-quarter results showing revenue of US$1,159 million versus US$1,059 million a year earlier, while net income eased to US$207 million from US$235 million and diluted earnings per share from continuing operations slipped to US$1.35 from US$1.49. At the same time, the company lifted its 2026 revenue outlook to US$4.60 billion–US$4.64 billion and guided third-quarter revenue of US$1.14 billion–US$1.16 billion, underscoring how clinical sequencing...

Illumina stock has more than doubled over the past year, yet valuation checks are split, with a Discounted Cash Flow (DCF) estimate pointing to upside while market multiples lean rich at the current US$205.10 share price. Illumina has returned 116.7% over the past year, which puts extra focus on whether today’s price still offers a reasonable margin between market value and business fundamentals. Stronger demand for clinical sequencing can support expectations for future cash flows, while...

Illumina (ILMN) is back in focus after its Q2 2026 results beat expectations on both revenue and earnings, prompting the company to lift full year guidance and outline priorities in clinical sequencing and multi omics. See our latest analysis for Illumina. Illumina’s recent guidance raise and Q2 beat come after a strong run in the stock, with a 90 day share price return of 47.16% and a 1 year total shareholder return of 116.67%. However, the 5 year total shareholder return is down 57.56%,...

The developer of blood-based cancer tests still has a bright future.

Illumina (NASDAQ:ILMN) raised its 2026 revenue and earnings outlook after reporting second-quarter results that exceeded its expectations, supported by clinical sequencing demand, elevated NovaSeq X placements and higher consumables volume. Second-quarter revenue totaled $1.16 billion, up 9.5% from

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates.

Illumina CEO Jacob Thaysen discusses the company's earnings, genomic medicine opportunities and the potential for artificial intelligence in life sciences on "Bloomberg The Close."

Moby summary of Illumina, Inc.'s Q2 2026 earnings call

Illumina Inc (ILMN) reports 9.5% revenue growth in Q2 2026, led by robust clinical demand and NovaSeq X placements, prompting an upward revision to full-year EPS guidance.

Clinical momentum and NovaSeq X placements drive revenue guidance raise.

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Illumina (ILMN) delivered earnings and revenue surprises of +6.50% and +3.36%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Genomics company Illumina (NASDAQ:ILMN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 per share was 6.8% above analysts’ consensus estimates.

Francis deSouza, who previously served as COO and president of security products at Google Cloud, takes over on Aug. 10

Scale AI said on Thursday it had named former Google Cloud executive Francis DeSouza as ‌chief executive officer, effective August 10, as the ‌AI company looks to expand its data and applications businesses. DeSouza will succeed Jason ​Droege, who has served as interim CEO since June last year. Droege will work with deSouza in the coming months to support the transition, Scale said.

Eli Lilly (NYSE:LLY) has joined Illumina's Billion Cell Atlas alliance as a foundational participant. The alliance is building what is described as the world's largest genome-wide genetic perturbation dataset. The Billion Cell Atlas is sequencing hundreds of millions of cells to map disease mechanisms and find new drug targets. Eli Lilly enters this genomic data effort with a stock that has seen very strong multi year appreciation. NYSE:LLY is trading at $1,210.02, with the share price up...

Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday after market close. Here’s what to expect.

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Standard BioTools (LAB) said Tuesday that it has agreed to sell its Mass Cytometry business to Multi

The fund has delivered strong returns, but the price you pay today asks you to accept less compensation for risk than you could get from the government.

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

Danaher's latest earnings call saw analysts repeatedly test one sore spot in an otherwise solid quarter, and management's answers reveal the key risk for investors now.

AstraZeneca (LSE:AZN) has been in focus after Illumina highlighted progress on the Billion Cell Atlas alliance. AstraZeneca is a founding member of this initiative, which uses large scale genomic and CRISPR data to support future drug discovery. See our latest analysis for AstraZeneca. Despite AstraZeneca's participation in the Billion Cell Atlas and the new Zegfrovy licensing deal, the 30 day share price return is down 6.64% and the 90 day share price return is down 9.09%, while the 1 year...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 10% return has closely followed the S&P 500.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, forming an alliance focused on mapping human disease biology using large-scale genomic data and AI-driven drug discovery. The collaboration aims to build a detailed reference of cellular and genetic information across diseases, supporting the discovery of new drug targets. Eli Lilly enters this alliance with strong recent stock performance, with the share price at $1,146.9 and the stock up 51.5% over the...

Cathie Wood Trims AMD to Fund Bigger SpaceX Bet

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

The German Regional Court of Munich ruled that Illumina and its German subsidiary infringed Element Biosciences patents covering DNA sequencing imaging methods. The court ordered Illumina to stop supplying the affected sequencing systems and consumables in Germany and to recall infringing products from the market. The ruling includes legal and financial obligations for Illumina and could influence related patent disputes in other regions. Illumina (NasdaqGS:ILMN) is facing a significant...

If you’re an Alamar Biosciences (ALMR) shareholder, Friday was a good day. The stock climbed +7.3%, closing the session at a new 52-week high of $28.42. That’s a tidy gain on a day when the S&P 500 barely nudged up +0.4% and some key industry peers actually lost ground.